RTW Biotech Opportunities Ltd (RTW) ORD NPV

Sell:$1.79Buy:$1.81$0.01 (0.56%)

FTSE All Share:1.06%
Market closed |
Prices delayed by at least 15 minutes
Sell:$1.79
Buy:$1.81
Change:$0.01 (0.56%)
Market closed |
Prices delayed by at least 15 minutes
Sell:$1.79
Buy:$1.81
Change:$0.01 (0.56%)
Market closed |
Prices delayed by at least 15 minutes

Trust Information

About this company

RTW Biotech Opportunities Ltd is a Guernsey-based company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. The Company invests in companies developing therapies and technologies that can significantly improve patients' lives. The Company seeks to achieve its investment objective by leveraging the Investment Manager's data-driven pipeline of assets to invest in life sciences companies across various therapeutic categories and product types (including genetic medicines, biologics, traditional modalities, such as small molecule pharmaceuticals and antibodies, and medical devices). It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life. The Company's portfolio is managed by RTW Investments, LP.

Objective

The Company seeks to achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies. It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life.

Costs

  • Ongoing charge1.75%
  • Annual management charge -
  • Performance feeYes

Fee structure

An annual management fee of 1.25% of the NAV. If the compounded NAV return exceeds 8% p.a., the manager will be entitled to a performance fee of 20%.

Value Assessment

  • Value Assessment review date5 December 2024
  • Value Assessment next review date5 December 2025
  • Is Assessment of Value required under COLL?No
  • Outcome of COLL Assessment of Valuen/a
  • Outcome of PRIN Value Assessment or reviewProduct expected to provide fair value for reasonably foreseeable period
  • Other review related to value and or charges -
  • Further information-
Click to see more

Key facts

  • Currency
    USD
  • Benchmark
    Russell 2000 Biotech Growth
  • Shares in issue
    327.22m
  • Gross gearing
    0.00%
  • EPIC
    RTW
  • ISIN
    GG00BKTRRM22
  • Domicile
    Guernsey
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview of the company, currency, shares in issue, EPIC, location, exchange, index, website, Data sourced by LSEG. Objective, Costs, Fee Structure, Key facts including Benchmark, Gross gearing are provided by MorningStar.